

# Comparison of blood loss following the use of chlorhexidine acetate to saline for lavage during primary total knee replacement

<b>Submission date</b> 30/09/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 30/09/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 17/04/2015	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr M Divekar

**Contact details**  
Royal Cornwall Hospitals NHS Trust  
Treliske  
Truro  
United Kingdom  
TR1 3LJ  
+44 (0)1872 253960  
abc@email.com

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N0202133839

# Study information

## Scientific Title

Comparison of blood loss following the use of chlorhexidine acetate to saline for lavage during primary total knee replacement

## Study objectives

Is there an increase (statistically significant) in blood loss following use of chlorhexidine acetate to lavage the knee in total knee replacement?

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Double-blind randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Surgery: Knee arthroplasty

## Interventions

130 volunteers will have saline or chlorhexidine acetate used to lavage and blood loss estimated at 48 hours.

## Intervention Type

Drug

## Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

Chlorhexidine acetate

**Primary outcome measure**

Excess of 50 ml blood loss in chlorhexidine acetate group will be considered significant.

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/07/2003

**Completion date**

31/03/2006

## Eligibility

**Key inclusion criteria**

130 patients

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

130

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/07/2003

**Date of final enrolment**

31/03/2006

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

Royal Cornwall Hospitals NHS Trust

Truro

United Kingdom  
TR1 3LJ

## Sponsor information

### Organisation

Department of Health

### Sponsor details

Richmond House  
79 Whitehall  
London  
United Kingdom  
SW1A 2NL

### Sponsor type

Government

### Website

<http://www.dh.gov.uk/Home/fs/en>

## Funder(s)

### Funder type

Government

### Funder Name

Royal Cornwall Hospitals NHS Trust (UK)

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration